Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Res. 2013 Oct 3;11(12):1585–1596. doi: 10.1158/1541-7786.MCR-13-0358

Figure 7. Co-targeting VEGF and FGFR sensitize HNSCC tumors to bevacizumab.

Figure 7

(A) Resistant xenografts (n=12) were randomized into four treatment groups receiving saline, bevacizumab, PD173074 or a combination of both. Bevacizumab and PD173074 were administered intraperitoneally at 8mg/kg and 25mg/kg respectively. Treatment with PD173074 alone resulted in a modest but statistically significant decrease in tumor growth (# P=0.0369). Combined knockdown of VEGF and FGFR completely abrogated tumor growth (* P=0.0427, combination vsbevacizumab alone; P=0.0451, combination vs PD173074 alone). (B–C) CD31 staining in resistant xenografts showed significantly reduced microvessel density in the combination group compared to bevacizumab or PD173074 alone (* P=0.012, combination vsbevacizumab alone; P=0.0364, combination vs PD173074 alone).